{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T04:43:21Z","timestamp":1759466601847,"version":"build-2065373602"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:00:00Z","timestamp":1759449600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009736","name":"Allm\u00e4nna Sjukhusets i Malm\u00f6 Stiftelse f\u00f6r Bek\u00e4mpande av Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009736","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>The aim of this study is to describe how the use of diagnostic imaging for prostate cancer (PCa) has evolved over time and to determine whether there are any differences in access to diagnostic imaging, type of cancers detected, and mortality based on the education level of patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>11,063 men were recruited between 1991 and 1996 and then prospectively followed until 2020. All new cases of PCa were recorded. At baseline, data on education level, heredity for cancer, and health status were collected. Incident PCa diagnoses during the study period were ascertained through record matching with national healthcare registers. The registers provided more detailed data on the cancer type and imaging performed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>1,816 men with diagnosed were PCa during the study period were included. No differences were seen between education levels in regard to access to diagnostic methods or tumour aggressiveness at diagnosis. Furthermore, no differences were seen in PCa-specific mortality, but there was higher overall mortality among individuals with a lower education level. During the study period, the use of plain radiographic examinations decreased, while the use of computed tomography (CT), prostate magnetic resonance imaging (MRI), and positron emission tomography\/computed tomography (PET\/CT) increased.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Early detection and diagnostic methods for PCa have evolved over the last 30 years. In a healthcare system where men diagnosed with PCa had equal access to diagnostic pathways, no differences are seen in PCa specific mortality. Nevertheless, men with lower education level still had higher overall mortality.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1636292","type":"journal-article","created":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T04:11:51Z","timestamp":1759464711000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Prostate cancer diagnostics: evolution over 30 years and the impact of education level \u2013 a prospective population-based study"],"prefix":"10.3389","volume":"15","author":[{"given":"Leon","family":"Will","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik","family":"Thimansson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johan","family":"Bengtsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anders","family":"Bjartell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophia","family":"Zackrisson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik","family":"Baubeta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMms1914228","article-title":"Reconsidering prostate cancer mortality - the future of PSA screening","volume":"382","author":"Welch","year":"2020","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2021.09.006","article-title":"Epidemiology and prevention of prostate cancer","volume":"4","author":"Gandaglia","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.7248","article-title":"The diagnosis and treatment of prostate cancer: A review","volume":"317","author":"Litwin","year":"2017","journal-title":"Jama."},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/nejm198710083171501","article-title":"Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate","volume":"317","author":"Stamey","year":"1987","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/nejm199104253241702","article-title":"Measurement of prostate-specific antigen in serum as a screening test for prostate cancer","volume":"324","author":"Catalona","year":"1991","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2008.09.019","article-title":"New horizons in prostate cancer imaging","volume":"70","author":"Ravizzini","year":"2009","journal-title":"Eur J Radiol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801993","article-title":"MRI-targeted or standard biopsy for prostate-cancer diagnosis","volume":"378","author":"Kasivisvanathan","year":"2018","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.eururo.2019.06.023","article-title":"Prostate magnetic resonance imaging, with or without magnetic resonance imaging-targeted biopsy, and systematic biopsy for detecting prostate cancer: A cochrane systematic review and meta-analysis","volume":"77","author":"Drost","year":"2020","journal-title":"Eur Urol."},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/bju.16211","article-title":"Opportunistic prostate-specific antigen testing in Norwegian men: a public health challenge","volume":"133","author":"Albertsen","year":"2024","journal-title":"BJU Int"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/pcan.2017.32","article-title":"The impact of sociodemographic factors and PSA screening among low-income Black and White men: data from the Southern Community Cohort Study","volume":"20","author":"Moses","year":"2017","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.31272","article-title":"Socioeconomic status and diagnosis, treatment, and mortality in men with prostate cancer. Nationwide population-based study","volume":"142","author":"Tomic","year":"2018","journal-title":"Int J Cancer."},{"key":"B12","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1136\/jech.2004.023531","article-title":"Indicators of socioeconomic position (part 1)","volume":"60","author":"Galobardes","year":"2006","journal-title":"J Epidemiol Community Health"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1080\/21681805.2021.1881612","article-title":"The G\u00d6TEBORG prostate cancer screening 2 trial: a prospective, randomised, population-based prostate cancer screening trial with prostate-specific antigen testing followed by magnetic resonance imaging of the prostate","volume":"55","author":"Kohestani","year":"2021","journal-title":"Scand J Urol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1080\/21681805.2017.1411392","article-title":"Eighteen-year follow-up of the G\u00f6teborg Randomized Population-based Prostate Cancer Screening Trial: effect of sociodemographic variables on participation, prostate cancer incidence and mortality","volume":"52","author":"Hugosson","year":"2018","journal-title":"Scand J Urol."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp2209151","article-title":"Screening for prostate cancer","volume":"388","author":"Pinsky","year":"2023","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2022.06.008","article-title":"Designing and implementing a population-based organised prostate cancer testing programme","volume":"8","author":"Alterbeck","year":"2022","journal-title":"Eur Urol Focus."},{"key":"B17","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1111\/bju.16143","article-title":"A pilot study of an organised population-based testing programme for prostate cancer","volume":"133","author":"Alterbeck","year":"2024","journal-title":"BJU Int"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djt175","article-title":"Prostate cancer imaging trends after a nationwide effort to discourage inappropriate prostate cancer imaging","volume":"105","author":"Makarov","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1097\/00008469-200112000-00003","article-title":"The Malm\u00f6 Diet and Cancer Study: representativity, cancer incidence and mortality in participants and non-participants","volume":"10","author":"Manjer","year":"2001","journal-title":"Eur J Cancer Prev"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-11-450","article-title":"External review and validation of the Swedish national inpatient register","volume":"11","author":"Ludvigsson","year":"2011","journal-title":"BMC Public Health"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dys068","article-title":"Cohort profile: the national prostate cancer register of Sweden and prostate cancer data base Sweden 2","volume":"42","author":"Van Hemelrijck","year":"2013","journal-title":"0. Int J Epidemiol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e5780","DOI":"10.1002\/pds.5780","article-title":"Consistency between the national patient register and the swedish cancer register","volume":"33","author":"Sakakibara","year":"2024","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B23","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1080\/02841860802247664","article-title":"The completeness of the Swedish Cancer Register: a sample survey for year 1998","volume":"48","author":"Barlow","year":"2009","journal-title":"Acta Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2024.03.012","article-title":"Mortality risks associated with depression in men with prostate cancer","volume":"7","author":"Crump","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2014.10.025","article-title":"Evaluation of data quality in the National Prostate Cancer Register of Sweden","volume":"51","author":"Tomic","year":"2015","journal-title":"Eur J Cancer."},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.Cd009094","article-title":"The impact of user fees on access to health services in low- and middle-income countries","volume":"2011","author":"Lagarde","year":"2011","journal-title":"Cochrane Database systematic Rev"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.55388","article-title":"Financial toxicity among patients with breast cancer worldwide: A systematic review and meta-analysis","volume":"6","author":"Ehsan","year":"2023","journal-title":"JAMA Netw Open"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1136\/bmjonc-2024-000400","article-title":"Associations between socioeconomic factors and PSA testing in a population-based organised testing programme and routine healthcare: a register-based study of 50-year-old men","volume":"3","author":"Emil","year":"2024","journal-title":"BMJ Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.4081\/jphr.2020.1711","article-title":"The impact of interventions addressing socioeconomic inequalities in cancer-related outcomes in high-income countries: A systematic review","volume":"9","author":"Bygrave","year":"2020","journal-title":"J Public Health Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.34932","article-title":"Socioeconomic inequality in prostate cancer diagnostics, primary treatment, rehabilitation, and mortality in Sweden","volume":"155","author":"Str\u00f6mberg","year":"2024","journal-title":"Int J Cancer."},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.02.033","article-title":"Prostate imaging reporting and data system version 2.1: 2019 update of prostate imaging reporting and data system version 2","volume":"76","author":"Turkbey","year":"2019","journal-title":"Eur Urol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1097\/cu9.0000000000000173","article-title":"Clinical and prostate multiparametric magnetic resonance imaging findings as predictors of general and clinically significant prostate cancer risk: A retrospective single-center study","volume":"17","author":"Massanova","year":"2023","journal-title":"Curr Urol."},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/pros.24761","article-title":"The detection rate for prostate cancer in systematic and targeted prostate biopsy in biopsy-naive patients, according to the localization of the lesion at the mpMRI: A single-center retrospective observational study","volume":"84","author":"Massanova","year":"2024","journal-title":"Prostate."},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics13111939","article-title":"Reliability of multiparametric magnetic resonance imaging in patients with a previous negative biopsy: comparison with biopsy-na\u00efve patients in the detection of clinically significant prostate cancer","volume":"13","author":"Barone","year":"2023","journal-title":"Diagnostics (Basel)."},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12112594","article-title":"PSMA PET-CT in the diagnosis and staging of prostate cancer","volume":"12","author":"Combes","year":"2022","journal-title":"Diagnostics (Basel)."},{"key":"B36","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s11864-024-01181-9","article-title":"Impact of PSMA PET on prostate cancer management","volume":"25","author":"Weiner","year":"2024","journal-title":"Curr Treat Options Oncol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1186\/s12885-020-07178-5","article-title":"Education level as a predictor of survival in patients with multiple myeloma","volume":"20","author":"Xu","year":"2020","journal-title":"BMC Cancer."},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1093\/eurpub\/ckw261","article-title":"Education predicts cervical cancer survival: a Lithuanian cohort study","volume":"27","author":"Vincer\u017eevskiene","year":"2017","journal-title":"Eur J Public Health"},{"key":"B39","unstructured":"Ortiz-Ospina ER\n              M\n            \n          \n          Healthcare spending ourworldindata.org\n          \n          2017"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1636292\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T04:11:53Z","timestamp":1759464713000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1636292\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,3]]},"references-count":39,"alternative-id":["10.3389\/fonc.2025.1636292"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1636292","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,3]]},"article-number":"1636292"}}